

From: [REDACTED]  
Sent: 18 February 2008 12:43  
To: Natalie Bemrose  
Cc: [REDACTED]; [REDACTED]  
( [REDACTED] )  
Subject: Comments re STA: Adalimumab for the treatment of psoriasis

Follow Up Flag: Follow up  
Flag Status: Red

Dear Natalie,

These are the comments from the British Association of Dermatologists re the above appraisal.

Comments were sought from our Therapy, Guidelines and Audit subcommittee and our Biologics Group and all feedback was positive. It was felt that the appraisal demonstrated a good understanding of the data and the general need for biologics in the management of severe psoriasis.

Re your specific headings:

i) Do you consider that all of the relevant evidence has been taken into account? Yes

ii) Do you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence, and that the preliminary views on the resource impact and implications for the NHS are appropriate? Yes, agree

iii) Do you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS? Yes, excellent

iv) Are there any equality related issues that need special consideration that are not covered in the ACD? No

I would be grateful if you could acknowledge receipt of these comments

Regards,

[REDACTED]

[REDACTED]

---

Delivered via MessageLabs

---